Teachers Retirement System of The State of Kentucky Has $2.97 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Teachers Retirement System of The State of Kentucky raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 55.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,189 shares of the medical equipment provider's stock after acquiring an additional 11,798 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Lantheus were worth $2,969,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the fourth quarter worth $27,000. Summit Securities Group LLC acquired a new stake in Lantheus during the 4th quarter worth about $37,000. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new stake in Lantheus during the 3rd quarter valued at approximately $60,000. Institutional investors own 99.06% of the company's stock.

Lantheus Trading Up 1.3 %

Shares of LNTH stock traded up $1.29 on Tuesday, reaching $103.99. 157,619 shares of the stock were exchanged, compared to its average volume of 951,569. Lantheus Holdings, Inc. has a twelve month low of $65.76 and a twelve month high of $126.89. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of 17.29 and a beta of 0.20. The business's 50 day moving average price is $97.80 and its 200 day moving average price is $95.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on LNTH shares. Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has an average rating of "Moderate Buy" and an average target price of $129.43.

Insider Buying and Selling at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 63,109 shares of company stock valued at $6,016,046. Corporate insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.